Peptide Supplement vs Drug Classification Rules

The line between a peptide supplement and a peptide drug is one of the most important distinctions in the industry. Getting it wrong can lead to legal trouble, product seizures, and serious fines.

Why Classification Matters

How a peptide product is classified determines everything about how it can be made, sold, and marketed. Supplements and drugs follow very different rules.

Drug products must go through years of clinical trials and win FDA approval before they can be sold. This process costs hundreds of millions of dollars.

Dietary supplements can go to market without FDA pre-approval. But they must follow different rules about manufacturing, labeling, and what claims they can make.

If a product is classified as a drug but sold as a supplement, the company is breaking the law. The FDA has shut down many businesses for this exact mistake.

According to the FDA's own website, a dietary supplement is defined as a product intended to supplement the diet that contains one or more dietary ingredients. The key word is "intended," and the FDA looks at how a product is marketed to determine its intent.

The Legal Framework

Several laws and regulations govern peptide classification in the United States. Understanding these is essential for any company in this space.

The Dietary Supplement Health and Education Act (DSHEA)

DSHEA was passed in 1994. It created the legal category of "dietary supplement" and set the rules for how these products are regulated.

Under DSHEA, a dietary supplement must contain a "dietary ingredient." This includes vitamins, minerals, herbs, amino acids, and substances used to supplement the diet.

Some peptides made from amino acids may qualify as dietary ingredients. But this depends on many factors, including the specific peptide and how it is marketed.

The Federal Food, Drug, and Cosmetic Act (FD&C Act)

The FD&C Act defines what a drug is. Any product intended to diagnose, treat, cure, mitigate, or prevent a disease is a drug under this law.

This definition is based on intended use, not chemistry. A peptide that could be a supplement becomes a drug the moment it is marketed for treating a disease.

The intended use is determined by looking at labels, websites, social media, and any other communications about the product. Even a single disease claim can flip a product from supplement to drug.

Factor	Dietary Supplement	Drug
FDA pre-approval	Not required	Required
Clinical trials	Not required	Required
Manufacturing standards	cGMP for supplements	cGMP for drugs (stricter)
Allowed claims	Structure/function only	Disease treatment claims
Cost to market	Low to moderate	Very high
Time to market	Weeks to months	Years to decades
Labeling rules	Supplement Facts panel	Drug Facts or prescription label

How the FDA Determines Classification

The FDA uses several factors to decide whether a peptide product is a supplement or a drug. Understanding these factors helps companies stay on the right side of the line.

Intended Use

Intended use is the single most important factor. The FDA looks at what the company says about the product, not just what is on the label.

If a company says its peptide "supports muscle health," that may be a valid structure/function claim for a supplement. If it says the peptide "treats muscle wasting disease," that is a drug claim.

The distinction can be very subtle. Companies must choose their words with extreme care.

Prior Market History

If a substance was sold as a dietary supplement before 1994 (when DSHEA was passed), it has a stronger claim to supplement status. New ingredients introduced after 1994 need a New Dietary Ingredient (NDI) notification.

Many peptides are too new to have this prior market history. This means they may need to go through the NDI process before being sold as supplements.

Chemical Structure

The FDA considers whether a peptide is identical to a substance already approved or being studied as a drug. If a peptide is the subject of an approved drug or an active IND (Investigational New Drug) application, it generally cannot be sold as a supplement.

This rule has affected several popular peptides. When a peptide enters the drug approval pipeline, supplement companies that sell the same peptide can be forced to stop.

"The classification of a peptide as a supplement or drug is not a gray area to the FDA. It is determined by clear legal criteria, and companies that ignore these criteria do so at their own risk.", Marc Ullman, FDA regulatory attorney

How the Product Is Used

The FDA also looks at how consumers actually use the product. If most buyers use a peptide for disease treatment rather than general wellness, the FDA may view it as a drug.

Consumer testimonials, online forums, and social media posts can all be used as evidence of intended use. Companies must monitor and manage what is said about their products.

Structure/Function Claims vs. Drug Claims

The type of claims you make about a peptide product is the clearest dividing line between supplement and drug classification. Getting claims right is essential.

What Are Structure/Function Claims?

Structure/function claims describe how a product affects the body's normal structure or function. They do not mention any disease.

Examples include "supports joint health," "promotes healthy skin," and "helps maintain muscle mass." These claims are allowed for dietary supplements.

Companies must have evidence to support structure/function claims. They must also include a disclaimer stating the product has not been evaluated by the FDA.

What Are Drug Claims?

Drug claims state or imply that a product can diagnose, treat, cure, mitigate, or prevent a disease. These claims trigger drug classification.

Examples include "treats arthritis," "cures acne," and "prevents osteoporosis." Any claim that names or implies a disease is a drug claim.

Even indirect references to diseases can be problematic. Saying a peptide "reduces inflammation associated with autoimmune conditions" crosses the line.

Claim Type	Example	Classification
Structure/function	"Supports healthy joints"	Supplement
Structure/function	"Promotes collagen production"	Supplement
Disease claim	"Treats osteoarthritis"	Drug
Disease claim	"Reduces tumor growth"	Drug
Borderline	"Supports immune defense against infections"	Likely drug
Borderline	"Helps maintain healthy blood sugar levels"	May be supplement

The FDA has issued hundreds of warning letters to supplement companies for making drug claims about their products. Many of these letters are public and can be found on the FDA's website. Reading them is a good way to learn where the line is.

The New Dietary Ingredient (NDI) Process

If your peptide was not sold as a supplement before October 15, 1994, you likely need to file an NDI notification with the FDA before selling it.

The NDI notification tells the FDA about the new ingredient and provides evidence that it is safe. The FDA then has 75 days to review it and respond.

An NDI notification is not an approval. The FDA can object if it has safety concerns, but it does not formally approve new dietary ingredients.

Many companies skip the NDI process, but this is risky. Without a filed NDI notification, the FDA can take action against your product at any time.

What the NDI Notification Requires

You must provide the identity of the new ingredient, its manufacturing process, and evidence of safety. The safety evidence can include published studies, toxicology data, and history of safe use.

The more data you provide, the stronger your notification. Weak or incomplete submissions are more likely to receive objections from the FDA.

Common Reasons for FDA Objections

The FDA often objects to NDI notifications when the safety data is insufficient. Relying only on history of use without toxicology studies is a common weakness.

Another common problem is failing to show that the specific form and dose of the peptide is safe. The FDA wants to see data on the exact product being sold, not just the general ingredient.

For a deeper look at how regulatory actions affect peptide businesses, read our article on DEA scheduling impacts.

Enforcement Actions

The FDA has several tools to enforce classification rules. Companies that sell drug products as supplements face serious consequences.

Warning Letters

The most common first step is a warning letter. This letter identifies the violations and gives the company a chance to fix them.

Warning letters are public records. They can damage your company's reputation even if you fix the problems quickly.

Product Seizures

The FDA can seize products that violate the law. This means federal agents can physically take your inventory from your warehouse.

Seizures are costly and disruptive. They can shut down your business entirely while the legal process plays out.

Injunctions

An injunction is a court order that forces a company to stop selling a product. Violating an injunction can lead to criminal contempt charges.

The FDA uses injunctions when companies do not respond to warning letters. They are a powerful tool that can end a business.

Criminal Prosecution

In the most serious cases, the FDA refers violations to the Department of Justice for criminal prosecution. Individuals and companies can face fines and prison time.

Criminal cases are rare but real. They tend to involve companies that repeatedly ignore warnings or engage in fraud.

"The FDA has been increasing its enforcement against peptide products marketed with drug claims. Companies in this space should expect more scrutiny, not less.", Steven Tave, former director of FDA's Office of Dietary Supplement Programs

How to Stay Compliant

Following the rules is not just good ethics; it is good business. Here are practical steps to keep your peptide products properly classified.

Work with a Regulatory Attorney

Before launching any peptide product, consult with an attorney who specializes in FDA law. They can review your product, claims, and marketing to identify risks.

This investment pays for itself many times over. A single warning letter or seizure costs far more than legal review fees.

Review All Marketing Materials

Every label, website page, social media post, and advertisement must be reviewed for compliance. One rogue claim can put your entire business at risk.

Create a review process where a trained person checks all materials before they go public. Document these reviews for your records.

File NDI Notifications When Needed

If your peptide qualifies as a new dietary ingredient, file the notification. It takes time and effort, but it protects your business.

Work with a consultant who has experience filing NDI notifications. They can help you build the strongest possible submission.

Train Your Team

Everyone in your company who talks about your products needs compliance training. This includes sales staff, customer service, social media managers, and executives.

People who do not understand the rules can accidentally make drug claims. Regular training prevents these costly mistakes.

For companies building compliance capabilities, our guide on regulatory affairs teams explains how to hire and organize the right people.

Monitor Third-Party Claims

Even if your company is careful, retailers, influencers, and customers might make drug claims about your products. The FDA can hold you responsible for third-party claims you know about or should have known about.

Set up monitoring systems to catch unauthorized claims. Take action quickly to correct them when found.

International Considerations

Classification rules differ by country. A peptide that is a supplement in one country might be a drug in another.

The European Union has its own rules under the Novel Food Regulation and the Medicinal Products Directive. Canada uses the Natural Health Products Regulations. Australia has the Therapeutic Goods Act.

Companies selling internationally must comply with each country's rules separately. What works in the U.S. may not work anywhere else.

Country/Region	Supplement Framework	Key Difference from U.S.
United States	DSHEA	Least restrictive pre-market rules
European Union	Novel Food Regulation	Pre-market safety assessment required
Canada	Natural Health Products Regs	Pre-market licensing required
Australia	Therapeutic Goods Act	Listed or registered product categories
Japan	Food with Health Claims	Specific health claim approval system

The Future of Peptide Classification

The rules around peptide classification are evolving. Several trends will shape the future.

The FDA is expected to tighten enforcement against peptides sold with drug claims. The growing popularity of peptides in the wellness market has drawn more regulatory attention.

New legislation could update DSHEA for the first time in decades. Any changes would have major impacts on what peptides can be sold as supplements.

As more peptides enter the drug approval pipeline, more supplement products could be forced off the market. Companies should watch the FDA's IND filings closely.

The best strategy is to build a strong compliance program now. Companies that play by the rules will be best positioned to survive and thrive as regulations evolve.

Frequently Asked Questions

Can a peptide be sold as both a supplement and a drug?

Generally, no. Under the FD&C Act, if a substance is first approved as a drug or is under active IND investigation, it usually cannot be marketed as a dietary supplement. However, if a substance was marketed as a supplement before drug studies began, there may be an exception. This is a complex legal area that requires expert guidance.

What happens if my supplement gets a warning letter from the FDA?

You must respond to the warning letter within the timeframe stated, usually 15 business days. Your response should explain what corrective actions you are taking. If you do not respond or fix the problems, the FDA can escalate to seizures, injunctions, or criminal prosecution. Taking warning letters seriously and acting fast is critical.

Do I need to register with the FDA to sell peptide supplements?

Yes, all facilities that manufacture, process, pack, or hold dietary supplements must register with the FDA. You must also submit a Supplement Facts label and notify the FDA within 30 days of marketing a product. These requirements are separate from the NDI notification process.

How do I know if my peptide needs an NDI notification?

If the peptide was not marketed as a dietary supplement in the U.S. before October 15, 1994, it is likely a new dietary ingredient. You can check the FDA's NDI database and review historical sales records. When in doubt, consult a regulatory attorney who specializes in dietary supplement law.

Can I make health claims about peptide supplements on social media?

You can make structure/function claims on social media, but not drug claims. The same rules that apply to labels and websites apply to social media posts. The FDA monitors social media and has issued warning letters based on posts that made disease claims. Train your social media team on these rules and review all posts before publishing.